Jefferies Ractchets Numbes on Biogen (BIIB) Higher Post Q2
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Biogen (BIIB) Underpromise/Overdeliver Strategy Plays Well on Wall Street
July 25, 2013 10:55 AM EDTLeerink Swann today maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $271. Biogen reported strong Q2 results, with notable strength in Tecfidera. Meanwhile, sales of Tysabri appear to be suffering.
"We believe the strong 2Q13 quarter will lead... More
Biogen Idec, Inc. (BIIB) Tops Q2 EPS by 37c; Issues Solid Guidance
July 25, 2013 7:09 AM EDTBiogen Idec, Inc. (NASDAQ: BIIB) reported Q2 EPS of $2.30, $0.37 better than the analyst estimate of $1.93. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.62 billion.
Biogen Idec, Inc. sees FY2013 EPS of $8.25-$8.50, versus the consensus of $8.22.
Revenue gains were led by the performance of our marketed therapies:
AVONEX® revenues increased 2% year-over-year to $774 million. The total was comprised of $479 million in U.S.... More
